keyword
MENU ▼
Read by QxMD icon Read
search

CNS lymphoma

keyword
https://www.readbyqxmd.com/read/29780646/incorporating-cystatin-c-to-predict-methotrexate-elimination-in-patients-with-cns-lymphoma-and-suspicious-renal-function
#1
Jason N Barreto, Allison L McClanahan, Andrew D Rule, Carrie A Thompson, Erin Frazee
High-dose methotrexate (MTX; ≥1 g/m2 ) is a renally eliminated and nephrotoxic first-line therapy for central nervous system (CNS) lymphoma. Creatinine-based estimation of renal function is the recommended approach to dosing MTX in these cases, but nonrenal determinants of creatinine production and elimination in cancer patients such as malnutrition and cachexia lead to overestimation of glomerular filtration rate (GFR) by this method and a heightened risk for drug toxicity. Serum cystatin C is one of the first readily available, relatively inexpensive, endogenous biomarkers to emerge as a practical adjunct to creatinine for estimation of renal function for drug dosing...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29777009/feasibility-of-cxcr4-directed-radioligand-therapy-in-advanced-diffuse-large-b-cell-lymphoma
#2
Constantin Lapa, Heribert Hänscheid, Malte Kircher, Andreas Schirbel, Gerd Wunderlich, Rudolf Werner, Samuel Samnick, Jörg Kotzerke, Hermann Einsele, Andreas Buck, Hans-Jürgen Wester, Götz Ulrich Grigoleit
We have recently reported on our experience with C-X-C-motif chemokine receptor 4- (CXCR4-) directed radioligand therapy (RLT) in multiple myeloma and acute leukemia. Methods: Six patients with heavily pre-treated relapsed diffuse large B cell lymphoma (DLBCL) (3 males, 3 females; aged, 54±8 years) underwent CXCR4-directed RLT in combination with conditioning chemotherapy and allogeneic stem cell transplantation (SCT). In 2 patients, radioimmunotherapy (RIT) targeting CD20 or CD66 was added to enhance anti-lymphoma activity...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29768119/exploratory-analysis-of-brigatinib-activity-in-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-and-brain-metastases-in-two-clinical-trials
#3
D Ross Camidge, Dong-Wan Kim, Marcello Tiseo, Corey J Langer, Myung-Ju Ahn, Alice T Shaw, Rudolf M Huber, Maximilian J Hochmair, Dae Ho Lee, Lyudmila A Bazhenova, Kathryn A Gold, Sai-Hong Ignatius Ou, Howard L West, William Reichmann, Jeff Haney, Tim Clackson, David Kerstein, Scott N Gettinger
Purpose In patients with crizotinib-treated, anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC), initial disease progression often occurs in the CNS. We evaluated brigatinib, a next-generation ALK inhibitor, in patients with ALK-positive NSCLC with brain metastases. Patients and Methods Patients with ALK-positive NSCLC received brigatinib (90 to 240 mg total daily) in a phase I/II trial (phI/II; ClinicalTrials.gov identifier: NCT01449461) and in the subsequent randomized phase II trial ALTA (ALK in Lung Cancer Trial of AP26113; ClinicalTrials...
May 16, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29748847/exposure-response-analysis-of-alectinib-in-crizotinib-resistant-alk-positive-non-small-cell-lung-cancer
#4
Peter N Morcos, Eveline Nueesch, Felix Jaminion, Elena Guerini, Joy C Hsu, Walter Bordogna, Bogdana Balas, Francois Mercier
PURPOSE: Alectinib is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor that is active in the central nervous system (CNS). Alectinib demonstrated robust efficacy in a pooled analysis of two single-arm, open-label phase II studies (NP28673, NCT01801111; NP28761, NCT01871805) in crizotinib-resistant ALK-positive non-small-cell lung cancer (NSCLC): median overall survival (OS) 29.1 months (95% confidence interval [CI]: 21.3-39.0) for alectinib 600 mg twice daily (BID). We investigated exposure-response relationships from final pooled phase II OS and safety data to assess alectinib dose selection...
May 10, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29743796/increased-incidence-of-post-transplant-lymphoproliferative-disorder-in-autoimmune-liver-disease-an-irish-national-experience
#5
Ahmed Abu-Shanab, Yasser Ged, Naeem Ullah, Diarmaid Houlihan, Aiden McCormick
Background: Post-Transplant Lymphoproliferative Disorder (PTLD) is a well-recognized complication post solid organs transplant. PTLD represents a broad spectrum of abnormalities ranging from an infectious mononucleosis like illness to malignant lymphoma. Methods: A retrospective study was performed by collecting data of orthotopic liver transplant (OLT) patients in the National Liver Unit in Ireland from December 1993 to December 2014. Data was analyzed to identify PTLD patients and determine their demographic details, the indication for liver transplant, presenting symptoms, immunosuppression regimens, Epstein"Barr virus (EBV) status and PTLD outcome...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29742278/conditional-relative-survival-among-long-term-survivors-of-adolescent-and-young-adult-cancers
#6
Chelsea Anderson, Andrew B Smitherman, Hazel B Nichols
BACKGROUND: Many studies have examined long-term outcomes after childhood cancer, but few address outcomes for adolescent and young adult (AYA; those aged 15-39 years) cancer survivors. Conditional survival reflects changing mortality risk with time since cancer diagnosis and is a useful measure for planning long-term follow-up care. METHODS: Using the Surveillance, Epidemiology, and End Results registry 9 database, the authors identified a cohort of AYA patients diagnosed with a first malignant cancer between 1973 and 2009 and followed through 2014...
May 9, 2018: Cancer
https://www.readbyqxmd.com/read/29741758/excellent-real-world-outcomes-of-adults-with-burkitt-lymphoma-treated-with-codox-m-ivac-plus-or-minus-rituximab
#7
Katie Y Zhu, Kevin W Song, Joseph M Connors, Heather Leitch, Michael J Barnett, Khaled Ramadan, Graham W Slack, Yasser Abou Mourad, Donna L Forrest, Donna E Hogge, Stephen H Nantel, Sujaatha Narayanan, Thomas J Nevill, Maryse M Power, David S Sanford, Heather J Sutherland, Tracy Tucker, Cynthia L Toze, Laurie H Sehn, Raewyn Broady, Alina S Gerrie
Treatment of Burkitt lymphoma (BL) with intensive, multi-agent chemotherapy with aggressive central nervous system (CNS) prophylaxis results in high cure rates, although no regimen is standard of care. We examined population-based survival outcomes of adults with BL treated with a modified combination of cyclophosphamide, vincristine, doxorubicin, prednisone and systemic high-dose methotrexate (MTX) (CODOX-M) with IVAC (ifosfamide, mesna, etoposide, cytarabine and intrathecal MTX) (CODOX-M/IVAC) ± rituximab over a 15-year period in British Columbia...
May 9, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29740389/a-rare-case-of-composite-dural-extranodal-marginal-zone-lymphoma-and-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma
#8
REVIEW
Mark Bustoros, Benjamin Liechty, David Zagzag, Cynthia Liu, Timothy Shepherd, Deborah Gruber, Bruce Raphael, Dimitris G Placantonakis
Background: Primary extranodal marginal zone lymphoma (MZL) of the dura is a rare neoplastic entity in the central nervous system (CNS). Methods: We used literature searches to identify previously reported cases of primary dural MZL. We also reviewed clinical, pathologic, and radiographic data of an adult patient with concurrent dural MZL and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Results: We identified 104 cases of dural MZL in the literature...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29732319/epstein-barr-virus-in-gliomas-cause-association-or-artifact
#9
REVIEW
Saghir Akhtar, Semir Vranic, Farhan Sachal Cyprian, Ala-Eddin Al Moustafa
Gliomas are the most common malignant brain tumors and account for around 60% of all primary central nervous system cancers. Glioblastoma multiforme (GBM) is a grade IV glioma associated with a poor outcome despite recent advances in chemotherapy. The etiology of gliomas is unknown, but neurotropic viruses including the Epstein-Barr virus (EBV) that is transmitted via salivary and genital fluids have been implicated recently. EBV is a member of the gamma herpes simplex family of DNA viruses that is known to cause infectious mononucleosis (glandular fever) and is strongly linked with the oncogenesis of several cancers, including B-cell lymphomas, nasopharyngeal, and gastric carcinomas...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29719098/allogeneic-hematopoietic-cell-transplant-following-crizotinib-monotherapy-for-relapsed-refractory-anaplastic-large-cell-lymphoma
#10
Tami D John, Swati Naik, Kathryn Leung, Ghadir Sasa, Caridad Martinez, Robert A Krance
Relapsed ALK-positive ALCL often is responsive to CRZ monotherapy. The subsequent role of allogeneic HCT after achieving second remission is poorly understood. We report 6 children who underwent allogeneic HCT for relapsed ALCL after CRZ. Age at transplant ranged from 10.7 to 22.6 years. Follow-up ranged from 0.9 to 4.5 years. All patients engrafted. Three of 4 patients that received a reduced-toxicity conditioning regimen containing fludarabine, alemtuzumab, and low-dose irradiation showed progressive mixed chimerism...
May 2, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29703403/intraventricular-treatment-of-secondary-central-nervous-system-lymphoma-case-study-and-literature-overview
#11
Dariusz Szczepanek, Ewa Wąsik-Szczepanek, Agnieszka Szymczyk, Tomasz Gromek, Ewelina Grywalska, Monika Podhorecka, Marek Hus
Secondary nervous system lymphoma (SCNSL) is a rare extranodal form of non-Hodgkin lymphoma (NHL). This applies to a particular form of lymphoma that does not originally derive from the central nervous system (CNS); it can be both an isolated form of relapse or a systemic part of disease progression. Due to poor prognosis and a lack of established algorithms of therapeutic procedures, it is a big challenge for physicians from many specializations. In our study, we present an interesting case of a patient with a relapsed form of SCNSL for whom a unique form of treatment was used - intraventricular administration of rituximab and methotrexate...
February 6, 2018: Neurologia i Neurochirurgia Polska
https://www.readbyqxmd.com/read/29697005/primary-breast-diffuse-large-b-cell-lymphoma-treatment-strategies-and-patterns-of-failure
#12
Ethan B Ludmir, Sarah A Milgrom, Chelsea C Pinnix, Jillian R Gunther, Jason Westin, Yasuhiro Oki, Luis E Fayad, L Jeffrey Medeiros, Bouthaina S Dabaja, Loretta J Nastoupil
Treatment strategies and outcomes were assessed in 25 patients with primary breast diffuse large B-cell lymphoma (PB-DLBCL) treated between 1995 and 2016. We specifically investigated the timing of recurrence, and the roles of radiotherapy (RT) and central nervous system prophylaxis (CNS PPX). Fifty-two percent of patients received RT, and 28% received CNS PPX. Fourteen patients (56%) experienced recurrence, with 76% of relapses occurring ≥24 months after diagnosis, in contrast to reports supporting the use of 24-month event-free survival as a surrogate endpoint in the general DLBCL population...
April 26, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29682187/prognostic-value-of-early-18f-fdg-pet-scanning-evaluation-in-immunocompetent-primary-cns-lymphoma-patients
#13
Rudy Birsen, Estelle Blanc, Lise Willems, Barbara Burroni, Marielle Legoff, Emmanuelle Le Ray, Sylvain Pilorge, Sawsen Salah, Aude Quentin, Benedicte Deau, Patricia Franchi, Marguerite Vignon, Laurence Mabille, Charles Nguyen, Yioula Kirova, Pascale Varlet, Myriam Edjlali, Edouard Dezamis, Khê Hoang-Xuan, Carole Soussain, Caroline Houillier, Diane Damotte, Johan Pallud, Didier Bouscary, Jerome Tamburini
Primary central nervous system lymphoma (PCNSL) is a rare topographic variant of diffuse large B-cell lymphoma (DLBCL). While prognostic scales are useful in clinical trials, no dynamic prognostic marker is available in this disease. We report here the prognostic value of early metabolic response by 18F-FDG PET scanner (PET) in 25 newly diagnosed immunocompetent PCNSL patients. Induction treatment consisted of four cycles of Rituximab, Methotrexate and Temozolamide (RMT). Based on patient's general condition, consolidation by high-dose Etoposide and Aracytine was given to responding patients...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29680874/utility-and-proposed-algorithm-of-csf-flow-cytometry-in-hematologic-malignancies
#14
Bernard Tawfik, Larry Brown, Frankling Fuda, Weina Chen, Shuang Niu, Joseph Sailors, Navid Sadeghi
In patients with hematologic malignancies, multiparameter flow cytometry (FCM) offers greater sensitivity than cytology in detecting malignant cells in the initial cerebrospinal fluid (CSF) specimen. However, the role of FCM in assessment of subsequent specimens is unclear. We developed an algorithm to reduce the number of low-yield FCM tests without significant impact on clinically meaningful results. Patients with hematologic malignancies were studied in a derivation cohort, and the following algorithm was developed: (1) cytology and FCM on all initial samples, (2) cytology on all subsequent samples, and (3) FCM on subsequent samples only if previous FCM was positive...
April 21, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29675948/pattern-of-care-and-survival-of-anaplastic-lymphoma-kinase-rearranged-non-small-cell-lung-cancer-alk-nsclc-in-an-australian-metropolitan-tertiary-referral-centre-a-retrospective-cohort-analysis
#15
Malinda Itchins, Sarah A Hayes, Anthony J Gill, Wendy Cooper, Rachel O'Connell, Viive M Howell, Stephen J Clarke, Nick Pavlakis
AIM: To report on the pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+NSCLC) in a real-world retrospective cohort from an Australian tertiary referral center. METHODS: Individuals with a pathological diagnosis of ALK+NSCLC via immunohistochemistry and fluorescence in situ hybridization and a radiological diagnosis of stage IV disease were eligible. Patients were identified via the Pathology Department specimen database and electronic patient chart review...
April 19, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29674128/diagnostic-value-of-cerebrospinal-fluid-cxcl13-for-acute-lyme-neuroborreliosis-a-systemic-review-and-meta-analysis
#16
REVIEW
Tobias Armin Rupprecht, Kirsi Marjaana Manz, Volker Fingerle, Christian Lechner, Matthias Klein, Markus Pfirrmann, Uwe Koedel
OBJECTIVES: The utility of cerebrospinal fluid (CSF) CXCL13 for diagnosis of acute Lyme neuroborreliosis (LNB) has been debated and the test is not yet routinely performed. This study's aim was to evaluate its overall diagnostic accuracy through meta-analysis. METHODS: Electronic searches in PubMed MEDLINE and Web of Science were performed to identify relevant articles published before January 2018. A summary receiver operating characteristic curve and an optimal cut-off were estimated modeling multiple cut-offs...
April 16, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29668860/alectinib-versus-chemotherapy-in-crizotinib-pretreated-anaplastic-lymphoma-kinase-alk-positive-non-small-cell-lung-cancer-results-from-the-phase-iii-alur-study
#17
S Novello, J Mazières, I-J Oh, J de Castro, M R Migliorino, Å Helland, R Dziadziuszko, F Griesinger, A Kotb, A Zeaiter, A Cardona, B Balas, H K Johannsdottir, A Das-Gupta, J Wolf
Background: This is the first trial to directly compare efficacy and safety of alectinib versus standard chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients who have progressed on, or were intolerant to, crizotinib. Patients and methods: ALUR (MO29750; NCT02604342) was a randomized, multicenter, open-label, phase III trial of alectinib versus chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive NSCLC patients previously treated with platinum-based doublet chemotherapy and crizotinib...
April 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29666949/precision-medicine-against-alk-positive-non-small-cell-lung-cancer-beyond-crizotinib
#18
REVIEW
Biagio Ricciuti, Andrea De Giglio, Carmen Mecca, Cataldo Arcuri, Sabrina Marini, Giulio Metro, Sara Baglivo, Angelo Sidoni, Guido Bellezza, Lucio Crinò, Rita Chiari
Anaplastic lymphoma kinase (ALK) rearrangements represent the molecular driver of a subset of non-small cell lung cancers (NSCLCs). Despite the initial response, virtually all ALK-positive patients develop an acquired resistance to the ALK inhibitor crizotinib, usually within 12 months. Several next-generation ALK inhibitors have been developed in order to overcome crizotinib limitation, providing an unprecedented survival for this subset of patients. The aim of this review to summarize the current knowledge on ALK tyrosine kinase inhibitors (TKIs) in the treatment of advanced ALK-positive NSCLC, focusing on the role of novel ALK inhibitors in this setting...
April 17, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29662870/primary-cns-high-grade-b-cell-lymphoma-with-rearrangements-of-myc-and-bcl6-a-case-report
#19
Appalanaidu Sasapu, Dinesh Atwal, Giovanni Insuasti-Beltran, Yogesh Jethava
No abstract text is available yet for this article.
March 2018: Blood Research
https://www.readbyqxmd.com/read/29662531/cystic-brain-metastases-in-alk-rearranged-non-small-cell-lung-cancer
#20
REVIEW
Guilherme Nader Marta, Renata Rodrigues da Cunha Colombo Bonadio, Renata Eiras Martins, Henrique Bortot Zuppani, Gilberto de Castro
The central nervous system (CNS) is a common site of disease progression in patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK)-rearrangement treated with crizotinib. Cystic brain metastases (CBM) have been recently identified as one possible variant of this disease. An illustrative case report is presented along with a literature review performed in order to track relevant papers about CBM in ALK-rearranged NSCLC, including possible pathophysiology, differential diagnosis and treatment options for this condition...
2018: Ecancermedicalscience
keyword
keyword
1439
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"